Posted by Michael Wonder on 28 Nov 2019
Verrica Pharmaceuticals announces FDA filing acceptance of new drug application for VP-102 for the treatment of molluscum contagiosum
27 November 2019 - PDUFA date assigned is 13 July 2020.
Verrica Pharmaceuticals today announced that its new drug application for VP-102 (cantharidin 0.7% topical solution), a proprietary topical therapy for the treatment of molluscum contagiosum (molluscum), has been accepted for filing by the U.S. FDA.
The application is based on positive results from two identical Phase 3 randomized, double-blind, multicenter clinical trials (CAMP-1 and CAMP-2) that evaluated the safety and efficacy of VP-102 compared to placebo in patients two years of age and older diagnosed with molluscum.
